PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy

Authors: Grivas, Petros, Koshkin, Vadim S., Chu, Xiangying, Cole, Suzanne, Jain, Rohit K., Dreicer, Robert, Cetnar, Jeremy P., Sundi, Debasish, Gartrell, Benjamin A., Galsky, Matthew D., Woo, Brianna, Li-Ning-Tapia, Elsa, Hahn, Noah M., Carducci, Michael A.

Source: In European Urology Oncology August 2024 7(4):914-922

Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin

Authors: Vlachou, Evangelia, Mamtani, Ronac, Hahn, Noah M., III, Burles Johnson, Hoffman-Censits, Jean, Nimgaonkar, Vivek

Source: In Clinical Genitourinary Cancer June 2024 22(3)

Clinicopathologic and Survival After Cystectomy Outcomes in Squamous Cell Carcinoma of the Bladder

Authors: Agrawal, Pranjal, Rostom, Mary, Alam, Ridwan, Florissi, Isabella, Biles, Michael, Rodriguez, Katherine, Hahn, Noah M., Johnson, Burles A., III, Matoso, Andres, Smith, Armine, Bivalacqua, Trinity J., Kates, Max, Hoffman-Censits, Jeannie, Patel, Sunil H.

Source: In Clinical Genitourinary Cancer December 2023 21(6):631-638

Checkpoint Inhibitors in Urothelial Carcinoma—Future Directions and Biomarker Selection

Authors: Meeks, Joshua J., Black, Peter C., Galsky, Matthew, Grivas, Petros, Hahn, Noah M., Hussain, Syed A., Milowsky, Matthew I., Steinberg, Gary D., Svatek, Robert S., Rosenberg, Jonathan E.

Source: In European Urology November 2023 84(5):473-483

A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non–muscle-invasive Bladder Cancer

Authors: Inman, Brant A., Hahn, Noah M., Stratton, Kelly, Kopp, Ryan, Sankin, Alex, Skinner, Eila, Pohar, Kamal, Gartrell, Benjamin A., Pham, Song, Rishipathak, Deepali, Mariathasan, Sanjeev, Davarpanah, Nicole, Carter, Corey, Steinberg, Gary D.

Source: In European Urology Oncology June 2023 6(3):313-320

A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study

Authors: Hahn, Noah M., O'Donnell, Michael A., Efstathiou, Jason A., Zahurak, Marianna, Rosner, Gary L., Smith, Jeff, Kates, Max R., Bivalacqua, Trinity J., Tran, Phuoc T., Song, Daniel Y., Baras, Alex S., Matoso, Andres, Choi, Woonyoung, Smith, Kellie N., Pardoll, Drew M., Marchionni, Luigi, McGuire, Bridget, Grace Phelan, Mary, Johnson, Burles A., III, O'Neal, Tanya, McConkey, David J., Rose, Tracy L., Bjurlin, Marc, Lim, Emerson A., Drake, Charles G., McKiernan, James M., Deutsch, Israel, Anderson, Christopher B., Lamm, Donald L., Geynisman, Daniel M., Plimack, Elizabeth R., Hallman, Mark A., Horwitz, Eric M., Al-Saleem, Essel, Chen, David Y.T., Greenberg, Richard E., Kutikov, Alexander, Guo, Gordon, Masterson, Timothy A., Adra, Nabil, Kaimakliotis, Hristos Z.

Source: In European Urology June 2023 83(6):486-494

Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer

Authors: Nadal, Rosa, Apolo, Andrea B., Girardi, Daniel M., Hahn, Noah M., Bellmunt, Joaquim

Source: In Urologic Oncology: Seminars and Original Investigations January 2023 41(1):27-34

A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma.

Authors: Pili, Roberto, Quinn, David I., Adra, Nabil, Logan, Theodore, Colligan, Sean, Burney, Heather N., Hahn, Noah M.

Source: Cancer Medicine; Apr2025, Vol. 14 Issue 7, p1-10, 10p

Sarcomatoid areas of urothelial carcinoma are enriched for CD163‐positive antigen‐presenting cells.

Authors: Johnson, Burles A, Parimi, Vamsi, Kamanda, Sonia, Corney, David C, Choi, Woonyoung, Hoffman‐Censits, Jean, Kates, Max, McConkey, David J, Hahn, Noah M, Matoso, Andres

Source: Journal of Pathology: Clinical Research; Mar2025, Vol. 11 Issue 2, p1-6, 6p

Subject Terms: ANTIGEN presenting cells, TUMOR microenvironment, MACROPHAGES, FIBROBLASTS, CELL adhesion molecules, TRANSITIONAL cell carcinoma

Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature

Authors: Aragaki, Adam K., Jing, Yuezhou, Hoffman-Censits, Jean, Choi, Woonyoung, Hahn, Noah M., Trock, Bruce J., McConkey, David J., Johnson, Burles A., III

Source: In European Urology Oncology June 2022 5(3):338-346

Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

Authors: Becker, Russell E.N., Meyer, Alexa R., Brant, Aaron, Reese, Adam C., Biles, Michael J., Harris, Kelly T., Netto, George, Matoso, Andres, Hoffman-Censits, Jean, Hahn, Noah M., Choi, Woonyoung, McConkey, David, Pierorazio, Phillip M., Johnson, Michael H., Schoenberg, Mark P., Kates, Max R., Baras, Alex, Bivalacqua, Trinity J.

Source: In European Urology March 2021 79(3):364-371

Primary tumor response to enfortumab vedotin with/without pembrolizumab in patients with upper tract urothelial cancer.

Authors: Vlachou, Evangelia, Hoffman-Censits, Jeannie, Singla, Nirmish, Hahn, Noah M., Johnson III, Burles Avner, Kates, Max, Patel, Sunil, Russell, Stephanie, Smith, Armine, Rourke, Kelli, Sedaghat, Farzad, McMahon, Timothy

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p684-684, 242p

A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4).

Authors: Hahn, Noah M., Zahurak, Marianna, Kaimakliotis, Hristos Z., Masterson, Timothy A., Adra, Nabil, Chen, David YT, Kutikov, Alexander, Geynisman, Daniel M., Smelser, Woodson W, Reimers, Melissa A, Anderson, Christopher B., Stein, Mark N., Baras, Alexander S, Colocho, Gabriela, Schwartz, Deborah G, McConkey, David James, Patel, Sunil H., Rahim, Bilal G., O'Donnell, Michael A., Kates, Max

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p667-667, 242p

Tumor immune microenvironment in non–muscle-invasive urothelial carcinoma of the bladder

Authors: Eich, Marie-Lisa, Chaux, Alcides, Guner, Gunes, Taheri, Diana, Mendoza Rodriguez, Maria Angélica, Rodriguez Peña, Maria Del Carmen, Baras, Alexander S., Hahn, Noah M., Drake, Charles, Sharma, Rajni, Bivalacqua, Trinity J., Rezaei, Katayoon, Netto, George J.

Source: In Human Pathology July 2019 89:24-32

The Microbiome and Genitourinary Cancer: A Collaborative Review

Authors: Markowski, Mark C., Boorjian, Stephen A., Burton, Jeremy P., Hahn, Noah M., Ingersoll, Molly A., Maleki Vareki, Saman, Pal, Sumanta K., Sfanos, Karen S.

Source: In European Urology April 2019 75(4):637-646

Role of Checkpoint Inhibition in Localized Bladder Cancer

Authors: Hahn, Noah M., Necchi, Andrea, Loriot, Yohann, Powles, Thomas, Plimack, Elizabeth R., Sonpavde, Guru, Roupret, Morgan, Kamat, Ashish M.

Source: In European Urology Oncology August 2018 1(3):190-198

Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma

Authors: Liao, Ross S., Gupta, Mohit, Schwen, Zeyad R., Patel, Hiten D., Kates, Max, Johnson, Michael H., Hahn, Noah M., McConkey, David, Bivalacqua, Trinity J., Pierorazio, Phillip M.

Source: In The Journal of Urology July 2018 200(1):68-73

Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer

Authors: Harshman, Lauren C., Tripathi, Abhishek, Kaag, Matthew, Efstathiou, Jason A., Apolo, Andrea B., Hoffman-Censits, Jean H., Stadler, Walter M., Yu, Evan Y., Bochner, Bernard H., Skinner, Eila C., Downs, Tracy, Kiltie, Anne E., Bajorin, Dean F., Guru, Khurshid, Shipley, William U., Steinberg, Gary D., Hahn, Noah M., Sridhar, Srikala S.

Source: In Clinical Genitourinary Cancer June 2018 16(3):213-218

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes

Authors: Galsky, Matthew D., Wang, Huan, Hahn, Noah M., Twardowski, Przemyslaw, Pal, Sumanta K., Albany, Costantine, Fleming, Mark T., Starodub, Alexander, Hauke, Ralph J., Yu, Menggang, Zhao, Qianqian, Sonpavde, Guru, Donovan, Michael J., Patel, Vaibhav G., Sfakianos, John P., Domingo-Domenech, Josep, Oh, William K., Akers, Nicholas, Losic, Bojan, Gnjatic, Sacha, Schadt, Eric E., Chen, Rong, Kim-Schulze, Seunghee, Bhardwaj, Nina, Uzilov, Andrew V.

Source: In European Urology May 2018 73(5):751-759

Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method

Authors: Chalfin, Heather J. ^{*, *}, Kates, Max ^*, van der Toom, Emma E., Glavaris, Stephanie, Verdone, James E., Hahn, Noah M., Pienta, Kenneth J., Bivalacqua, Trinity J., Gorin, Michael A.

Source: In Urology May 2018 115:82-86